Why Is Elevance Health (ELV) Stock Down -10.43% Today?
Key Takeaways
- Elevance Health shares plunged 10.43% in early trading on July 15, 2026, following the release of disappointing second-quarter 2025 earnings and a sharp cut to full-year profit guidance.
- The primary catalyst was an earnings miss: adjusted EPS of $8.84 fell short of analyst expectations of approximately $9.07, while full-year adjusted EPS guidance was slashed to roughly $30.00.
- Elevated medical cost trends in the company's Medicaid and Affordable Care Act (ACA) health plan businesses drove the benefit expense ratio to 88.9%, a 260-basis-point increase year over year.
- Sector-wide pressure weighed on managed care peers, as investors reassessed the impact of persistent utilization headwinds across the health insurance industry.
- Traders are now focused on upcoming Medicaid rate negotiations, ACA membership stabilization, and whether cost trends will moderate in the second half of the year.
Opening Summary
ELV, the parent company of Elevance Health, Inc. — one of the largest health insurers in the United States serving over 109 million consumers through its portfolio of medical, pharmacy, and care solutions — saw its stock tumble 10.43% on July 15, 2026. The shares were trading at $382.27 as of mid-morning, down sharply from the prior session's close of $426.79. The sell-off was triggered by the company's second-quarter 2025 earnings release, which revealed an adjusted earnings per share miss and a significant downward revision to its full-year profit outlook, citing persistently elevated medical costs in its government-sponsored health plans.
Earnings Miss and Guidance Cut Rattle Investors
The most immediate driver of the decline was Elevance Health's second-quarter 2025 financial results, reported before the market opened. While operating revenue of $49.4 billion exceeded consensus estimates and represented 14.3% year-over-year growth, adjusted diluted earnings per share came in at $8.84 — below the roughly $9.07 that Wall Street analysts had projected. The miss, though modest in percentage terms, was overshadowed by a far more consequential revision to the company's full-year outlook.
Management lowered its 2025 adjusted diluted EPS guidance to approximately $30.00, a substantial reduction from prior expectations. The company also set GAAP net income per diluted share guidance at approximately $24.10. This guidance cut, coming less than two months after ELV had reaffirmed its outlook, signaled that cost pressures were proving more stubborn than leadership had anticipated. CEO Gail K. Boudreaux acknowledged the challenging environment, stating that the updated outlook reflected "elevated medical cost trends in ACA and slower rate alignment in Medicaid."
Medical Cost Pressures and Segment Performance
The core operational challenge for ELV lies in its benefit expense ratio, which climbed to 88.9% in the second quarter — a 260-basis-point deterioration from the prior-year period. This metric, which measures the proportion of premium revenue spent on medical claims, reflects higher-than-expected utilization and acuity in the company's Medicaid and individual ACA health plan memberships. Days in Claims Payable stood at 43.9 days as of June 30, 2025, adjusted for the CareBridge acquisition, representing a slight sequential decline.
Within the Health Benefits segment, operating revenue rose 12% to $41.6 billion, but operating gain was pressured by the elevated medical cost trends. Medical membership declined by 212,000 sequentially to approximately 45.6 million, driven by lower Medicaid enrollment and attrition in the Individual ACA business. On a more positive note, the Carelon segment — which encompasses pharmacy services and care delivery solutions — delivered operating revenue of $18.1 billion, up 36% year over year, with operating gain increasing 33% to $0.9 billion, supported by recent acquisitions and growth in CarelonRx product revenue.
Market Context and Trading Activity
The sell-off in ELV shares occurred on significantly elevated volume, with the stock trading well above its average daily turnover as institutional and retail investors digested the guidance revision. The move rippled across the managed care sector, with several peers also trading lower in sympathy as the market reassessed the trajectory of medical cost trends across the industry. The broader market indices were relatively stable during the same period, indicating that the decline was company- and sector-specific rather than driven by macroeconomic forces.
From a technical perspective, the stock gapped down at the open, slicing through multiple support levels. The magnitude of the move pushed ELV toward the lower end of its 52-week range, reflecting the severity of the repricing as investors recalibrated earnings expectations for the remainder of 2025 and beyond.
Trending AI Robots
In volatile market environments like the one affecting ELV today, traders often seek tools that can help navigate rapidly changing conditions with discipline and speed. Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to identify opportunities across thousands of tickers in real time. These bots employ diverse strategies — ranging from swing trading and trend following to pattern recognition and momentum-based approaches — and only the strongest performers under current market conditions are featured in this dynamic, regularly updated section. Each bot varies by strategy, timeframe, performance metrics, and the symbols it trades, giving users a window into which algorithmic approaches are thriving right now. Exploring the Trending AI Robots page can provide valuable insight for those looking to complement their own research with data-driven, automated analysis.
What Comes Next for ELV
Looking ahead, the trajectory of ELV shares will likely hinge on several key factors. First, investors will closely monitor the outcome of July Medicaid rate negotiations, which cover approximately one-third of the company's Medicaid membership and could help stabilize margins if states agree to actuarially sound rate adjustments. Second, stabilization of the Individual ACA membership base following recent attrition will be critical to achieving the revised earnings targets. Third, the continued expansion of the Carelon platform — particularly in specialty pharmacy, behavioral health, and post-acute care — represents a potential offset to pressures in the core insurance business.
Risks remain tilted to the downside in the near term. If medical cost trends do not moderate as management expects, or if Medicaid rate alignment proves slower than anticipated, further guidance revisions cannot be ruled out. Additionally, potential policy changes affecting Medicaid enrollment and ACA subsidies introduce regulatory uncertainty. On the other hand, the company's diversified business model, strong capital position — with approximately $2.2 billion in parent company cash and investments — and ongoing share repurchase program provide some cushion. The company returned $2.0 billion to shareholders year-to-date through buybacks and dividends, and management expressed confidence in achieving at least 12% average annual growth in adjusted diluted EPS over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ELV in upward trend: price rose above 50-day moving average on August 18, 2026
ELV moved above its 50-day moving average on August 18, 2026 date and that indicates a change from a downward trend to an upward trend. In of 52 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on ELV as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ELV just turned positive on August 06, 2026. Looking at past instances where ELV's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for ELV crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ELV advanced for three days, in of 318 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where ELV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.935) is normal, around the industry mean (3.666). P/E Ratio (17.715) is within average values for comparable stocks, (149.731). Projected Growth (PEG Ratio) (1.418) is also within normal values, averaging (1.216). Dividend Yield (0.017) settles around the average of (0.020) among similar stocks. P/S Ratio (0.440) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ELV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of life, hospital and medical insurance plans
Industry ManagedHealthCare
Advertisement